Biomarkers in rosacea: A systematic review.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
11 Dec 2023
11 Dec 2023
Historique:
received:
25
08
2023
accepted:
14
11
2023
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
aheadofprint
Résumé
Rosacea is a chronic and psychologically ladened disease affecting 1%-3% of people worldwide. The identification and validation of biomarkers in rosacea patients has the potential to improve disease progression, support diagnosis, provide objective measures for clinical trials and aid in management. The objective of this review is to systematically identify all rosacea biomarkers, categorize them by type and identify trends to improve disease expression. Eligibility criteria for this review (PROSPERO CRD42023397510) include randomized controlled trials, case-control studies, cohort studies and other observational studies. No restrictions were placed on patient demographics (age, sex, ethnicity) or language of publication until February 2023. Quality of studies was assessed using the National Institute of Health quality assessment tool. The literature search was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A total of 805 unique articles were screened based on the applied inclusion and exclusion criteria. After the articles were screened based on title/abstract and full-text, a total of 38 studies were included, reporting on a total of 119 unique biomarkers. The results of this review and current rosacea pathogenic mechanisms provide the greatest support for the innate cathelicidin and inflammasome, T
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Tan J, Almeida LM, Bewley A, Cribier B, Dlova NC, Gallo R, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):431-438.
Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327-341. quiz 42-4.
Abram K, Silm H, Maaroos HI, Oona M. Risk factors associated with rosacea. J Eur Acad Dermatol Venereol. 2010;24(5):565-571.
Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013;69(6 Suppl 1):S27-S35.
Rohrich RJ, Griffin JR, Adams WP Jr. Rhinophyma: review and update. Plast Reconstr Surg. 2002;110(3):860-869. quiz 70.
Huynh TT. Burden of disease: the psychosocial impact of rosacea on a patient's quality of life. Am Health Drug Benefits. 2013;6(6):348-354.
Bodaghi A, Fattahi N, Ramazani A. Biomarkers: promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. Heliyon. 2023;9(2):e13323.
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1-2):4-13.
Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, et al. Biomarkers in atopic dermatitis-a review on behalf of the international eczema council. J Allergy Clin Immunol. 2021;147(4):1174-1190.e1.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Casas C, Paul C, Lahfa M, Livideanu B, Lejeune O, Alvarez-Georges S, et al. Quantification of demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol. 2012;21(12):906-910.
Liu T, Li J, Deng Z, Chen M, Sha K, Xiao W, et al. Increased serum levels of CCL3, CXCL8, CXCL9, and CXCL10 in rosacea patients and their correlation with disease severity. J Dermatol. 2022;49(5):525-533.
Topcu-Yilmaz P, Atakan N, Bozkurt B, Irkec M, Aban D, Mesci L, et al. Determination of tear and serum inflammatory cytokines in patients with rosacea using multiplex bead technology. Ocul Immunol Inflamm. 2013;21(5):351-359.
Helfrich YR, Maier LE, Cui Y, Fisher GJ, Chubb H, Fligiel S, et al. Clinical, histologic, and molecular analysis of differences between erythematotelangiectatic rosacea and telangiectatic photoaging. JAMA Dermatol. 2015;151(8):825-836.
Dajnoki Z, Beke G, Kapitany A, Mocsai G, Gaspar K, Ruhl R, et al. Sebaceous gland-rich skin is characterized by TSLP expression and distinct immune surveillance which is disturbed in rosacea. J Invest Dermatol. 2017;137(5):1114-1125.
Harden JL, Shih YH, Xu J, Li R, Rajendran D, Hofland H, et al. Paired transcriptomic and proteomic analysis implicates IL-1beta in the pathogenesis of papulopustular rosacea explants. J Invest Dermatol. 2021;141(4):800-809.
Mylonas A, Hawerkamp HC, Wang Y, Chen J, Messina F, Demaria O, et al. Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea. JCI. Insight. 2023;8(4):e151846.
Falay Gur T, Erdemir AV, Gurel MS, Kocyigit A, Guler EM, Erdil D. The investigation of the relationships of demodex density with inflammatory response and oxidative stress in rosacea. Arch Dermatol Res. 2018;310(9):759-767.
Gao C, Ge L, Chen D, Zhang M, Zhao L, Liu W, et al. Increased frequency of circulating classical monocytes in patients with rosacea. Clin Cosmet Investig Dermatol. 2021;14:1629-1636.
Jiang P, Liu Y, Zhang J, Liu Y, Li M, Tao M, et al. Mast cell stabilization: new mechanism underlying the therapeutic effect of intense pulsed light on rosacea. Inflamm Res. 2023;72(1):75-88.
Barton K, Nava A, Monroy DC, Pflugfelder SC. Cytokines and tear function in ocular surface disease. Adv Exp Med Biol. 1998;438:461-469.
Lam-Franco L, Perfecto-Avalos Y, Patino-Ramirez BE, Rodriguez GA. IL-1alpha and MMP-9 tear levels of patients with active ocular rosacea before and after treatment with systemic azithromycin or doxycycline. Ophthalmic Res. 2018;60(2):109-114.
Kim HB, Na EY, Yun SJ, Lee JB. The effect of capsaicin on neuroinflammatory mediators of rosacea. Ann Dermatol. 2022;34(4):261-269.
Yamasaki K, Kanada K, Macleod DT, Borkowski AW, Morizane S, Nakatsuji T, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011;131(3):688-697.
Shih YH, Xu J, Kumar A, Li R, Chang ALS. Alterations of immune and keratinization gene expression in papulopustular rosacea by whole transcriptome analysis. J Invest Dermatol. 2020;140(5):1100-1103.e4.
Suhng E, Kim BH, Choi YW, Choi HY, Cho H, Byun JY. Increased expression of IL-33 in rosacea skin and UVB-irradiated and LL-37-treated HaCaT cells. Exp Dermatol. 2018;27(9):1023-1029.
Hayran Y, Sen O, Firat Oguz E, Yucel C, Eren F, Kulcu Cakmak S, et al. Serum IL-17 levels in patients with rosacea. J Cosmet Dermatol. 2022;21(3):1147-1153.
Payne WG, Ko F, Anspaugh S, Wheeler CK, Wright TE, Robson MC. Down-regulating causes of fibrosis with tamoxifen: a possible cellular/molecular approach to treat rhinophyma. Ann Plast Surg. 2006;56(3):301-305.
Kim JY, Kim YJ, Lim BJ, Sohn HJ, Shin D, Oh SH. Increased expression of cathelicidin by direct activation of protease-activated receptor 2: possible implications on the pathogenesis of rosacea. Yonsei Med J. 2014;55(6):1648-1655.
Buhl T, Sulk M, Nowak P, Buddenkotte J, McDonald I, Aubert J, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways. J Invest Dermatol. 2015;135(9):2198-2208.
Zhao Z, Liu T, Liang Y, Cui W, Li D, Zhang G, et al. N2-polarized neutrophils reduce inflammation in rosacea by regulating vascular factors and proliferation of CD4(+) T cells. J Invest Dermatol. 2022;142(7):1835-1844.e2.
Hoang-Xuan T, Rodriguez A, Zaltas MM, Rice BA, Foster CS. Ocular rosacea. A histologic and immunopathologic study. Ophthalmology. 1990;97(11):1468-1475.
Muto Y, Wang Z, Vanderberghe M, Two A, Gallo RL, Di Nardo A. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 2014;134(11):2728-2736.
Sulk M, Seeliger S, Aubert J, Schwab VD, Cevikbas F, Rivier M, et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol. 2012;132(4):1253-1262.
Sener S, Akbas A, Kilinc F, Baran P, Erel O, Aktas A. Thiol/disulfide homeostasis as a marker of oxidative stress in rosacea: a controlled spectrophotometric study. Cutan Ocul Toxicol. 2019;38(1):55-58.
Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-980.
Agrahari G, Sah SK, Nguyen CT, Choi SS, Kim HY, Kim TY. Superoxide dismutase 3 inhibits LL-37/KLK-5-mediated skin inflammation through modulation of EGFR and associated inflammatory cascades. J Invest Dermatol. 2020;140(3):656-665.e8.
Yoon SH, Hwang I, Lee E, Cho HJ, Ryu JH, Kim TG, et al. Antimicrobial peptide LL-37 drives rosacea-like skin inflammation in an NLRP3-dependent manner. J Invest Dermatol. 2021;141(12):2885-2894.e5.
Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821-832.
Santarlasci V, Cosmi L, Maggi L, Liotta F, Annunziato F. IL-1 and T helper immune responses. Front Immunol. 2013;4:182.
Di Nardo A, Holmes AD, Muto Y, Huang EY, Preston N, Winkelman WJ, et al. Improved clinical outcome and biomarkers in adults with papulopustular rosacea treated with doxycycline modified-release capsules in a randomized trial. J Am Acad Dermatol. 2016;74(6):1086-1092.
Trave I, Micalizzi C, Cozzani E, Gasparini G, Parodi A. Papulopustular rosacea treated with ivermectin 1% cream: remission of the demodex mite infestation over time and evaluation of clinical relapses. Dermatol Pract Concept. 2022;12(4):e2022201.
Der Sarkissian S, Hessam S, Kirby JS, Lowes MA, Mintoff D, Naik HB, et al. Identification of biomarkers and critical evaluation of biomarker validation in hidradenitis suppurativa: a systematic review. JAMA Dermatol. 2022;158(3):300-313.